<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">31320869</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1662-6575</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Season>May-Aug</Season>
            </PubDate>
          </JournalIssue>
          <Title>Case reports in oncology</Title>
          <ISOAbbreviation>Case Rep Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Limbic Encephalitis Complicated with Small Cell Lung Cancer at the Time of Recurrence.</ArticleTitle>
        <Pagination>
          <StartPage>466</StartPage>
          <EndPage>472</EndPage>
          <MedlinePgn>466-472</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000501305</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic limbic encephalitis (PLE) is a rare neurologic disorder that can complicate various malignancies, including lung cancer. PLE is most frequently found the initial presentation of lung cancer. In this study, we reported the case of a 74-year-old Japanese woman who developed PLE after partial remission of small cell lung cancer (SCLC) by first-line systemic chemotherapy. Brain magnetic resonance imaging showed no metastatic tumor or cerebrovascular disease. Anti-glutamic acid decarboxylase (GAD) and anti-amphiphysin antibodies were detected in her serum. She was diagnosed as having PLE related to the recurrence of SCLC and received high-dose glucocorticoid, and sequentially systemic chemotherapy with amrubicin. Unfortunately, these treatments did not improve her disease progression and she died 4 months later. Although PLE rarely occurs at the time of SCLC recurrence, physicians should pay attention to PLE onset even after chemotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sadamatsu</LastName>
            <ForeName>Hironori</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurihara</LastName>
            <ForeName>Yuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Koichiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Komiya</LastName>
            <ForeName>Kazutoshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogusu</LastName>
            <ForeName>Shinsuke</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirakawa</LastName>
            <ForeName>Haruki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tashiro</LastName>
            <ForeName>Hiroki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakashima</LastName>
            <ForeName>Chiho</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Tomomi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sueoka-Aragane</LastName>
            <ForeName>Naoko</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Haematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>06</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Case Rep Oncol</MedlineTA>
        <NlmUniqueID>101517601</NlmUniqueID>
        <ISSNLinking>1662-6575</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-amphiphysin antibody</Keyword>
        <Keyword MajorTopicYN="N">Anti-glutamic acid decarboxylase antibody</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Small cell lung cancer</Keyword>
      </KeywordList>
      <CoiStatement>All authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31320869</ArticleId>
        <ArticleId IdType="pmc">PMC6616071</ArticleId>
        <ArticleId IdType="doi">10.1159/000501305</ArticleId>
        <ArticleId IdType="pii">cro-0012-0466</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G, PNS Euronetwork  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010 Mar;67((3)):330–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20212230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, et al.  Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study. Neurology. 2015 Jul;85((3)):235–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4516293</ArticleId>
            <ArticleId IdType="pubmed">26109714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007 May;2((1)):22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868710</ArticleId>
            <ArticleId IdType="pubmed">17480225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123((Pt 7)):1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, et al.  Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry. 1999 Feb;66((2)):214–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736210</ArticleId>
            <ArticleId IdType="pubmed">10071102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007 Dec;20((6)):732–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17992098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al.  Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008 Oct;131((Pt 10)):2553–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18687732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al.  Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005 Jul;58((1)):96–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15984030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010 Apr;257((4)):509–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20035430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015 Nov;27((6)):489–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
